DaviesTF. 2000. Growing an interest in autoimmune thyroid disease—an interview with Robert Volpe MD. Endocrinol Metab Clin N Am, 29:431–442.
2.
McKenzieJM. 2001. A thyroid-stimulating life: an interview with Dr. J. Maxwell McKenzie. Thyroid, 11:1035–1042.
3.
DaviesTF. 2021. The active times of Jerome Hershman, MD: an interview with the founding editor of thyroid about a life devoted to the thyroid gland (and other things). Thyroid, 31:1609–1612.
4.
PetaC, WengrafT, McKenzieJ. 2019. Facilitating the voice of disabled women: the biographic narrative interpretive method in action. J Acad Soc Sci, 14:515–527.
5.
RitchieDA. 2003. Doing Oral History: A Practical Guide. Oxford University Press, New York.
6.
AlbrightF, EllsworthR. 1929. Studies on the physiology of the parathyroid glands: I. Calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J Clin Invest, 7:183–201.
7.
AlbrightF. 1942. Pseudo-hypoparathyroidism—an example of “Seabright-Bantam syndrome”. Endocrinology, 30:922–932.
8.
SurksMI, LevensonD. 1962. Pseudohypoparathyroidism. Case report with observations on the difficulty in confirming the diagnosis. Ann Intern Med, 56:282–288.
9.
SurksMI, OppenheimerJH. 1963. Effect of penicillin on thyroxine-binding by plasma proteins. Endocrinology, 72:567–573.
10.
SurksMI, ChinnKS, MatoushLR. 1966. Alterations in body composition in man after acute exposure to high altitude. J Appl Physiol, 21:1741–1746.
11.
SurksMI. 1966. Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet). J Clin Invest, 45:1442–1451.
12.
SurksMI. 1966. Effect of hypoxia and high altitude on thyroidal iodine metabolism in the rat. Endocrinology, 78:307–315.
13.
OppenheimerJH, KoernerD, SchwartzHL, SurksMI. 1972. Specific nuclear triiodothyronine binding sites in rat liver and kidney. J Clin Endocrinol Metab, 35:330–333.
14.
SurksMI, KoernerDH, OppenheimerJH. 1975. In vitro binding of L-triiodothyronine to receptors in rat liver nuclei. Kinectics of binding, extraction properties, and lack of requirement for cytosol proteins. J Clin Invest, 55:50–60.
15.
SchwartzHL, SurksMI, OppenheimerJH. 1971. Quantitation of extrathyroidal conversion of L-thyroxine to 3,5,3'-triiodo-L-thyronine in the rat. J Clin Invest, 50:1124–1130.
16.
OppenheimerJH, SchwartzHL, SurksMI. 1972. Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. J Clin Invest, 51:2493–2497.
17.
SurksMI, OppenheimerJH. 1977. Concentration of L-thyroxine and L-triiodothyronine specifically bound to nuclear receptors in rat liver and kidney. Quantitative evidence favoring a major role of T3 in thyroid hormone action. J Clin Invest, 60:555–562.
18.
BermudezF, SurksMI, OppenheimerJH. 1975. High incidence of decreased serum triiodothyronine concentration in patients with nonthyroidal disease. J Clin Endocrinol Metab, 41:27–40.
19.
LifschitzBM, DefesiCR, SurksMI. 1978. Thyrotropin response to thyrotropin-releasing hormone in the euthyroid rat: dose-response, time course, and demonstration of partial refractoriness to a second dose of thyrotropin-releasing hormone. Endocrinology, 102:1775–1782.
20.
MaturloSJ, RosenbaumRL, PanC, SurksMI. 1980. Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma free thyroid hormone concentrations in patients with nonthyroidal diseases. J Clin Invest, 66:451–456.
21.
OrdeneKW, PanC, BarzelUS, SurksMI. 1983. Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma thyroid hormone concentrations in patients of advanced age. Metabolism, 32:881–888.
22.
AstierHS, DeFesiCR, SurksMI. 1980. Kinetics of deoxyribonucleic acid synthesis and replication of thyrotrophs and somatotrophs during development of hypothyroidism and L-triiodothyronine treatment of hypothyroid rats. Endocrinology, 106:1537–1548.
HupartKH, HodinRA, LazarMA, ShapiroLE, ChinWW, SurksMI. 1993. c-erb-A mRNA correlates with T3-receptor levels in liver and pituitary of tumor rats. Thyroid, 3:55–58.
25.
SurksMI. 1991. Thyroid-stimulating hormone: reference range validity. JAMA, 266:1573.
26.
SurksMI, SievertR. 1995. Drugs and thyroid function. N Engl J Med, 333:1688–1694.
27.
HollowellJG, StaehlingNW, FlandersWD, HannonWH, GunterEW, SpencerCA, BravermanLE. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 87:489–499.
28.
SurksMI, OrtizE, DanielsGH, SawinCT, ColNF, CobinRH, FranklynJA, HershmanJM, BurmanKD, DenkeMA, GormanC, CooperRS, WeissmanNJ. 2004. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA, 291:228–238.
29.
SurksMI, GoswamiG, DanielsGH. 2005. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab, 90:5489–5496.
30.
MeyerovitchJ, Rotman-PikielnyP, SherfM, BattatE, LevyY, SurksMI. 2007. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med, 167:1533–1538.
31.
SurksMI, HollowellJG. 2007. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab, 92:4575–4582.
32.
AtzmonG, BarzilaiN, HollowellJG, SurksMI, GabrielyI. 2009. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab, 94:1251–1254.
AtzmonG, BarzilaiN, SurksMI, GabrielyI. 2009. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. J Clin Endocrinol Metab, 94:4768–4775.
35.
RizzaRA, VigerskyRA, RodbardHW, LadensonPW, YoungWFJr., SurksMI, KahnR, HoganPF. 2003. A model to determine workforce needs for endocrinologists in the United States until 2020. Endocr Pract, 9:210–219.
36.
SurksMI. 2013. Milestones in thyroid research at Montefiore Medical Center, 1920–2011 history and personal reflections. Endocr Pract, 19:172–174.
